(Newswire.net — July 23, 2013) Today in the USA there is a huge problem that the medical community is facing. This problem is one that has been around for some years now and it is “High Cholesterol”. Researchers have been providing services for decades to tackle to this growing epidemic.
It’s not a very well known fact but there are two types of cholesterol they are known as LDL (Low-density lipoprotein) and HDL (High-density lipoprotein).
Bad Cholesterol: Low-Density lipoprotein or LDL will carry cholesterol right from your liver all the way to the cells that need it however if there is too much cholesterol being carried to the cells then it can caused a build-up in the artery walls which can lead to a disease in the arteries. This is why LDL is known as “bad cholesterol”.
Good Cholesterol: High-Density lipoprotein or HDL carries cholesterol away from the cells and back into the liver. Once the cholesterol reaches the liver it is then broken down or passed out of the body as a waste product. This is why a higher level of HDL is a good thing, it assists with the services your body need to complete to run efficiently.
The race for an all new product to help battle LDL is now on and in full swing. It seems that one promising thing in this line of drug development is an anti-body that contacts “PCSK9 inhibitors“. These inhibitors are being tested extensively and are said to impair the liver’s ability to efficiently filter out bad cholesterol (LDL) from the blood.
Last Sunday the drug development company Amgen made a public announcement stating that its experiments from PCSK9 inhibitors (which is known as AMG-145) so far have been revealing positive results.
When asked about the developments, James McKenney, the lead study author of the trials said,
“The feeling I had when I saw the results was the feeling I had when we were studying statins in our research centre… it’s important to note that these are early trial results that need to be studied in much larger populations, for longer durations.”
On another note Amgen’s competitors are now said to be testing out their own versions of the drug so it seems like it’s only a matter of time before a new drug will be released.
Contact:
Francine Bennett
913-526-3743